

Tabel 1. Reporting of association with HIV and recommendation of HIV testing stratified by type of guideline

	Number of guidelines identified	% of total	HIV was not mentioned n (%)	The association with HIV mentioned but testing not recommended n (%)	The association with HIV mentioned and testing was recommended n (%)	p-value for between-group difference in HIV testing recommendation	p-value testing recommended versus no testing recommendation
			Group 1	Group 2	Group 3		
All guidelines	77	100%	24 (31%)	23 (30%)	30 (39%)		
Indicator conditions	69	90%	21 (30%)	19 (28%)	29 (42%)	0,2206	0,1399
AIDS defining conditions	8	10%	3 (38%)	4 (50%)	1 (13%)		
Source of guidelines:							
National guidelines	47	61%	15 (32%)	18 (38%)	14 (30%)	0,032	0,0009
Specialty society guidelines	24	31%	5 (21%)	3 (13%)	16 (67%)		
Pharma guidelines	6	8%	4 (67%)	2 (33%)	0		
Guidelines for ICs:							
Sexually transmitted diseases	12	16%	4 (33%)	4 (33%)	4 (33%)	<0,0001	0,0003
Herpes Zoster	5	6%	3 (60%)	0	2 (40%)		
Malignant Lymphoma	12	16%	0	1 (8%)	11 (92%)		
Cervical Dysplasia	3	4%	2 (67%)	1 (33%)	0		
Cervical cancer	4	5%	3 (75%)	1 (25%)	0		
Anal dysplasia or anal cancer	3	4%	0	3 (100%)	0		
Hepatitis B - acute or chronic	5	6%	1 (20%)	2 (40%)	2 (40%)		
Hepatitis C - acute or chronic	6	8%	1 (17%)	0	5 (83%)		
Mononucleosis-like illness	7	9%	6 (86%)	1 (14%)	0		
Unexplained leukocytopenia and/or thrombocytopenia	7	9%	1 (14%)	3 (43%)	3 (43%)		
Seborrheic dermatitis /exanthema	2	3%	0	2 (100%)	0		
Community acquired pneumonia	3	4%	1 (33%)	1 (33%)	1 (33%)		
Pneumocystis pneumonia	3	4%	0	3 (100%)	0		
Unexplained lymphadenopathy	5	6%	2 (40%)	1 (20%)	2 (40%)		